Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Crinetics Pharmaceuticals (CRNX) Other Gross PP&E Adjustments (2017 - 2025)

Crinetics Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 9 years, most recently at -$41.7 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at -$41.7 million for Q4 2025, changed 0.32% from a year ago — trailing twelve months through Dec 2025 was -$41.7 million (changed 0.32% YoY), and the annual figure for FY2025 was -$41.7 million, changed 0.32%.
  • Other Gross PP&E Adjustments for Q4 2025 was -$41.7 million at Crinetics Pharmaceuticals, down from -$19.7 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for CRNX hit a ceiling of $6.6 million in Q2 2023 and a floor of -$42.8 million in Q4 2023.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$9.9 million (2022), compared with a mean of -$13.4 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 360.51% in 2022 and later plummeted 1967.97% in 2023.
  • Crinetics Pharmaceuticals' Other Gross PP&E Adjustments stood at -$1.5 million in 2021, then plummeted by 39.3% to -$2.1 million in 2022, then plummeted by 1967.97% to -$42.8 million in 2023, then grew by 2.36% to -$41.8 million in 2024, then grew by 0.32% to -$41.7 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$41.7 million (Q4 2025), -$19.7 million (Q3 2025), and -$17.6 million (Q2 2025) per Business Quant data.